Serum cystatin C is associated with subclinical atherosclerosis in patients with type 2 diabetes: A retrospective study

Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease
Yu Kyung ChungHyoung Woo Lee

Abstract

The aim of this study was to investigate the association between the serum cystatin C level and cardiovascular disease risk in patients with type 2 diabetes mellitus. We studied 523 patients with type 2 diabetes mellitus and calculated estimated 10-year risk of atherosclerotic cardiovascular disease (%). Subclinical atherosclerosis was defined as brachial-ankle pulse wave velocity ⩾1700 ms, indicating the presence of arterial stiffness. Cystatin C level was significantly higher in the subclinical atherosclerosis group (brachial-ankle pulse wave velocity ⩾ 1700 ms) than in the non-subclinical atherosclerosis group (brachial-ankle pulse wave velocity < 1700 ms) (7.54 ± 3.15 mg/L vs 10.04 ± 5.12 mg/L, p < 0.001). Subclinical atherosclerosis was mainly determined by age, duration of diabetes and cystatin C level, but not by serum creatinine, 10-year risk of atherosclerotic cardiovascular disease score and estimated glomerular filtration rate in the multiple linear regression analysis. In addition, an increase in cystatin C level was independently associated with the risk of subclinical atherosclerosis after adjusting for age, sex, duration of diabetes, smoking, hypertension, 10-year risk of atherosclerotic cardiovascular disease ri...Continue Reading

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jul 24, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Akira YamashinaYoshio Yamamoto
Sep 19, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Frans J HoekRaymond T Krediet
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·R Asmar
Dec 24, 2004·Diabetes Care·Jorge L GrossThemis Zelmanovitz
Mar 4, 2005·Journal of the American Society of Nephrology : JASN·Andrew SmithGiancarlo Viberti
May 20, 2005·The New England Journal of Medicine·Michael G ShlipakCatherine Stehman-Breen
Sep 27, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Tokuyuki KitaharaYoshihisa Nojima
Jan 31, 2006·Diabetes Care·Barbara V HowardRichard B Devereux
Jul 4, 2007·Circulation·Ernesto L SchiffrinJohannes F E Mann
Feb 26, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Lesley A StevensAndrew S Levey
Nov 19, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Sang Heon SongSeong-Jang Kim
Apr 10, 2009·Journal of the American Society of Nephrology : JASN·Magdalena MaderoUNKNOWN Health ABC Study
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Aug 29, 2009·Clinical Chemistry·Nevio TaglieriJuan Carlos Kaski
Jun 18, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tanvir Chowdhury TurinHirotsugu Ueshima
Jul 16, 2013·Clinical and Experimental Hypertension : CHE·Abdullah OzkokTevfik Ecder
Nov 27, 2016·Lancet·Angela C WebsterPhilip Masson

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.